Attovia Therapeutics has announced a $90 million Series C financing led by Deep Track Capital. The funding will support clinical studies for ATTO-1310 and ATTO-3712, as well as advance multiple earlier-stage projects.

Attovia Therapeutics, a clinical-stage biopharma company, has completed a $90 million Series C financing round. Led by Deep Track Capital, the round included new investors such as Vida Ventures and Sanofi Ventures, along with existing investors. The proceeds will fund early-stage clinical studies for treatments targeting chronic pruritus and atopic dermatitis. This financing is a testament to the company's promising platform and its focus on developing innovative therapies for immune-mediated diseases.